Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA), a Cayman Islands exempted company and emerging growth company.
Reporting Date: September 8, 2026 (Date of earliest event reported).
Event: Entry into an Amended and Restated Definitive Merger Agreement (A&R Merger Agreement) with Power Analytics Global Corp. (PAGC), a Delaware corporation engaged in artificial intelligence, advanced analytics, and quantum-resistant security solutions. This agreement amends and restates a prior agreement dated April 29, 2026.
Key Financial Metrics and Transaction Terms
- Closing Valuation: Fixed at US$2,850,000,000 (equity value of PAGC inclusive of APQC Inc. and UltraSolar intellectual property).
- Merger Consideration: PAGC shareholders will receive Domesticated DMAA Common Shares. The number of shares is calculated as the Closing Valuation divided by the Reference Price.
- Reference Price: The greater of US$10.75 or the per share redemption value of DMAA ordinary shares.
- Maximum Share Number: The Merger Consideration will not exceed 265,116,279 Domesticated DMAA Common Shares.
- Minimum Cash Condition: Available Closing Cash must be at least US$15,000,000. The target level is US$30,000,000.
- Indemnification Cap: 15% of the Closing Valuation (US$427,500,000) with a deductible of US$500,000.
- Debt Status: PAGC must be free of all material funded indebtedness at Closing, except for disclosed Bridge Financing and ordinary course trade payables.
Material Changes Versus Prior Agreement
- Valuation Structure: Replaced the previous target valuation of US$1.0 billion, Valuation Milestone Schedule, and Floor Valuation of US$300 million with a fixed Closing Valuation of US$2.85 billion.
- Target Scope: Clarified the transaction as a single-target combination with PAGC. A contingent amendment for a second target and a combined equity value of US$3.0 billion (from Omnibus Amendment No. 3) has not become effective and is void.
- Transaction Structure: Formalized the structure as a domestication of DMAA to Delaware followed by a merger of a subsidiary (Merger Sub) with and into PAGC.
- APQC Acquisition: Explicitly conditioned the Merger on PAGC completing the acquisition of 100% of APQC Inc. and the UltraSolar intellectual property prior to Closing.
Guidance, Outlook, Risks, and Contingencies
- Conditions to Closing: Includes shareholder approval, effectiveness of the Registration Statement (Form S-4), delivery of a Fairness Opinion by Newbridge Securities Corporation, and completion of the APQC Acquisition by December 31, 2026.
- Affiliated Transaction: The Merger is an affiliated business combination as PAGC and BV Advisory Partners, LLC (holding convertible notes) are under common principal ownership. Independent directors approved the transaction.
- PIPE Financing: The Company has the right to negotiate a Private Investment in Public Equity (PIPE), but no PIPE has been agreed to as of the filing date. Closing is not conditioned on a PIPE.
- Termination Rights: The agreement may be terminated if the Closing does not occur by April 29, 2027 (Outside Date), if the APQC Acquisition is not completed by December 31, 2026, or if the Minimum Cash Condition is not satisfied.
- Risks: Risks include failure to satisfy closing conditions, inability to secure financing, high redemption rates reducing Available Closing Cash, and uncertainties regarding the affiliated nature of the deal.
Important Facts for Investor Verification
- Verify the completion of the APQC Acquisition and the assignment of UltraSolar patents to APQC or PAGC, as this is a strict condition to Closing.
- Confirm the final Reference Price and the resulting number of Merger Consideration shares, which depend on shareholder redemption rates.
- Review the Fairness Opinion to be delivered by Newbridge Securities Corporation regarding the financial fairness of the Merger Consideration.
- Monitor the status of the Minimum Cash Condition (US$15 million floor) and whether a PIPE or other financing is secured to meet the US$30 million target.
- Check the definitive proxy statement/prospectus (Form S-4) for details on the post-merger capitalization, governance, and the specific ownership percentages of former PAGC stockholders versus existing DMAA shareholders.